Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

Leßmann ME, Saalfeld FC, Ruge L, Kauffmann-Guerrero D, Illini O, Stenzinger A, Minuth-Fuchs K, Rittmeyer A, Goetting I, Schildknecht K, Eul B, Schubart C, Rothschild SI, Grohé C, Armster K, Mohorčič K, Janzic U, Waller CF, Overbeck TR, Vesce R, Schulte H, Mauti LA, Stephan-Falkenau S, Wiesweg M, Faehling M, Gerstenmaier U, Schmid S, Kian W, Lozynskyy R, Ivanović M, Syrigos K, Simon R, Merkelbach-Bruse S, Wenzel C, Brückmann S, Herold S, Aust DE, Thomas M, Hochmair MJ, Tufman A, Rasokat A, National Network Genomic Medicine Lung Cancer (nNGM), Christopoulos P, Wermke M

Open source

DOI
10.1038/s41698-026-01486-y
Published
2026 Jun 29
Container
NPJ precision oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41698-026-01486-y,
  title = {Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.},
  author = {Leßmann ME and Saalfeld FC and Ruge L and Kauffmann-Guerrero D and Illini O and Stenzinger A and Minuth-Fuchs K and Rittmeyer A and Goetting I and Schildknecht K and Eul B and Schubart C and Rothschild SI and Grohé C and Armster K and Mohorčič K and Janzic U and Waller CF and Overbeck TR and Vesce R and Schulte H and Mauti LA and Stephan-Falkenau S and Wiesweg M and Faehling M and Gerstenmaier U and Schmid S and Kian W and Lozynskyy R and Ivanović M and Syrigos K and Simon R and Merkelbach-Bruse S and Wenzel C and Brückmann S and Herold S and Aust DE and Thomas M and Hochmair MJ and Tufman A and Rasokat A and National Network Genomic Medicine Lung Cancer (nNGM) and Christopoulos P and Wermke M},
  year = {2026},
  journal = {NPJ precision oncology},
  doi = {10.1038/s41698-026-01486-y},
  url = {https://doi.org/10.1038/s41698-026-01486-y}
}

RIS

TY  - JOUR
TI  - Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.
AU  - Leßmann ME
AU  - Saalfeld FC
AU  - Ruge L
AU  - Kauffmann-Guerrero D
AU  - Illini O
AU  - Stenzinger A
AU  - Minuth-Fuchs K
AU  - Rittmeyer A
AU  - Goetting I
AU  - Schildknecht K
AU  - Eul B
AU  - Schubart C
AU  - Rothschild SI
AU  - Grohé C
AU  - Armster K
AU  - Mohorčič K
AU  - Janzic U
AU  - Waller CF
AU  - Overbeck TR
AU  - Vesce R
AU  - Schulte H
AU  - Mauti LA
AU  - Stephan-Falkenau S
AU  - Wiesweg M
AU  - Faehling M
AU  - Gerstenmaier U
AU  - Schmid S
AU  - Kian W
AU  - Lozynskyy R
AU  - Ivanović M
AU  - Syrigos K
AU  - Simon R
AU  - Merkelbach-Bruse S
AU  - Wenzel C
AU  - Brückmann S
AU  - Herold S
AU  - Aust DE
AU  - Thomas M
AU  - Hochmair MJ
AU  - Tufman A
AU  - Rasokat A
AU  - National Network Genomic Medicine Lung Cancer (nNGM)
AU  - Christopoulos P
AU  - Wermke M
PY  - 2026
JO  - NPJ precision oncology
DO  - 10.1038/s41698-026-01486-y
UR  - https://doi.org/10.1038/s41698-026-01486-y
ER  -

APA

ME, L., FC, S., L, R., D, K., O, I., A, S., K, M., A, R., I, G., K, S., B, E., C, S., SI, R., C, G., K, A., K, M., U, J., CF, W., TR, O., R, V., H, S., LA, M., S, S., M, W., M, F., U, G., S, S., W, K., R, L., M, I., K, S., R, S., S, M., C, W., S, B., S, H., DE, A., M, T., MJ, H., A, T., A, R., (nNGM), N. N. G. M. L. C., P, C., & M, W. (2026). Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01486-y

Source records